JP2010520745A - 前立腺癌のリスクに寄与する遺伝子変異体 - Google Patents

前立腺癌のリスクに寄与する遺伝子変異体 Download PDF

Info

Publication number
JP2010520745A
JP2010520745A JP2009548801A JP2009548801A JP2010520745A JP 2010520745 A JP2010520745 A JP 2010520745A JP 2009548801 A JP2009548801 A JP 2009548801A JP 2009548801 A JP2009548801 A JP 2009548801A JP 2010520745 A JP2010520745 A JP 2010520745A
Authority
JP
Japan
Prior art keywords
seq
prostate cancer
allele
markers
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009548801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010520745A5 (enExample
Inventor
グドムンドソン，ユリウス
サレム，パトリック
Original Assignee
デコード・ジェネティクス・イーエイチエフ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デコード・ジェネティクス・イーエイチエフ filed Critical デコード・ジェネティクス・イーエイチエフ
Publication of JP2010520745A publication Critical patent/JP2010520745A/ja
Publication of JP2010520745A5 publication Critical patent/JP2010520745A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009548801A 2007-02-07 2008-02-07 前立腺癌のリスクに寄与する遺伝子変異体 Ceased JP2010520745A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS8604 2007-02-07
IS8654 2007-06-22
PCT/IS2008/000003 WO2008096375A2 (en) 2007-02-07 2008-02-07 Genetic variants contributing to risk of prostate cancer

Publications (2)

Publication Number Publication Date
JP2010520745A true JP2010520745A (ja) 2010-06-17
JP2010520745A5 JP2010520745A5 (enExample) 2011-03-31

Family

ID=39650503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009548801A Ceased JP2010520745A (ja) 2007-02-07 2008-02-07 前立腺癌のリスクに寄与する遺伝子変異体

Country Status (13)

Country Link
US (1) US8865400B2 (enExample)
EP (2) EP2115171B1 (enExample)
JP (1) JP2010520745A (enExample)
CN (1) CN102317470A (enExample)
AU (1) AU2008212117B2 (enExample)
BR (1) BRPI0807236A2 (enExample)
CA (1) CA2677994A1 (enExample)
IL (1) IL200197A (enExample)
IN (1) IN2009DN05722A (enExample)
MX (1) MX2009008461A (enExample)
NZ (1) NZ579401A (enExample)
SG (1) SG193026A1 (enExample)
WO (1) WO2008096375A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102068667B1 (ko) * 2019-02-28 2020-01-21 주식회사 프로카젠 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102068666B1 (ko) * 2019-02-28 2020-02-11 주식회사 프로카젠 인종 별 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR20200105374A (ko) * 2019-02-28 2020-09-07 주식회사 프로카젠 각 유전 변이 정보에 개별적인 가중치를 부여한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR20200105373A (ko) * 2019-02-28 2020-09-07 주식회사 프로카젠 유전 변이의 개수에 따른 예측력을 고려한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697360B2 (en) 2007-11-30 2014-04-15 Decode Genetics Ehf. Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
WO2009085196A1 (en) * 2007-12-21 2009-07-09 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
CN106951732B (zh) 2010-05-25 2020-03-10 加利福尼亚大学董事会 基于计算机的基因组序列分析系统
US9646134B2 (en) * 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
WO2012029080A1 (en) * 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
WO2012031207A2 (en) 2010-09-03 2012-03-08 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US9534256B2 (en) 2011-01-06 2017-01-03 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
CN103797120B (zh) * 2011-09-16 2017-04-12 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
CN103060433B (zh) * 2012-10-19 2014-12-03 卫生部北京医院 一种预测前列腺癌易感性的试剂盒和方法
AU2013349721B2 (en) * 2012-11-20 2019-03-28 A3P Biomedical Ab Prognostic method for individuals with prostate cancer
WO2017164699A1 (ko) * 2016-03-24 2017-09-28 서울대학교병원 (분사무소) 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발
KR101944927B1 (ko) 2016-03-24 2019-02-07 서울대학교산학협력단 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발
CN110596060B (zh) * 2019-09-12 2020-08-21 江南大学 一种检测前列腺特异性抗原的光谱分析中荧光传感器的构建方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511433A (ja) * 1996-06-03 2000-09-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 前立腺癌に関連する遺伝子の変化
JP2002529065A (ja) * 1998-11-06 2002-09-10 ミリアド・ジェネティックス・インコーポレイテッド 染色体１７ｑ連鎖−前立腺癌感受性遺伝子

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5288611A (en) 1983-01-10 1994-02-22 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
JPS60501339A (ja) 1983-01-10 1985-08-22 ジエン−プロ−ブ　インコ−ポレィテッド 生物を検出、同定又は定量する方法およびキット
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ES2155822T3 (es) 1990-12-06 2001-06-01 Affymetrix Inc Compuestos y su utilizacion en una estrategia de sintesis binaria.
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6287850B1 (en) 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
DE69527585T2 (de) 1994-06-08 2003-04-03 Affymetrix, Inc. Verfahren und Vorrichtung zum Verpacken von Chips
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
WO1997045559A1 (en) 1996-05-29 1997-12-04 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
ATE409226T1 (de) 1998-06-05 2008-10-15 Serono Genetics Inst Sa Polymorphe marker von prostatakarzinom tumorantigen-1 (pcta-1)
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
AU2003276973A1 (en) * 2002-09-25 2004-04-19 Amersham Biosciences (Sv) Corp. Detection methods
US20050136407A1 (en) 2003-12-19 2005-06-23 Cramer Scott D. Genetic polymorphisms in the prostate-specific antigen gene promoter
US20050255507A1 (en) 2004-02-17 2005-11-17 Jenkins Robert B Cytogenetically determined diagnosis and prognosis of proliferative disorders
WO2006063285A2 (en) 2004-12-10 2006-06-15 Sequenom, Inc. Methods for identifying risk of breast cancer or prostate cancer and treatments thereof
MX2007014447A (es) * 2005-05-18 2008-04-16 Decode Genetics Ehf Variantes en cromosoma 8q24.21 que confieren riesgo de cancer.
CA2667737A1 (en) * 2006-10-27 2008-05-02 Julius Gudmundsson Cancer susceptibility variants on chr8q24.21
US8697360B2 (en) * 2007-11-30 2014-04-15 Decode Genetics Ehf. Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511433A (ja) * 1996-06-03 2000-09-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 前立腺癌に関連する遺伝子の変化
JP2002529065A (ja) * 1998-11-06 2002-09-10 ミリアド・ジェネティックス・インコーポレイテッド 染色体１７ｑ連鎖−前立腺癌感受性遺伝子

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013010160; Ｎａｔｕｒｅ　Ｇｅｎｅｔｉｃｓ Ｖｏｌ．３９，　Ｎｏ．８, 200707, ｐｐ．９７７-９８３ *
JPN6013010161; Ｂｒｉｔｉｓｈ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃａｎｃｅｒ Ｖｏｌ．９６, 2007, ｐｐ．４９９-５０６ *
JPN7013000840; Ｊ．　Ｎａｔｌ．　Ｃａｎｃｅｒ．　Ｉｎｓｔ． Ｖｏｌ．９９, 200712, ｐｐ．１８３６-１８４４ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102068667B1 (ko) * 2019-02-28 2020-01-21 주식회사 프로카젠 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102068666B1 (ko) * 2019-02-28 2020-02-11 주식회사 프로카젠 인종 별 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR20200105374A (ko) * 2019-02-28 2020-09-07 주식회사 프로카젠 각 유전 변이 정보에 개별적인 가중치를 부여한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR20200105373A (ko) * 2019-02-28 2020-09-07 주식회사 프로카젠 유전 변이의 개수에 따른 예측력을 고려한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102371655B1 (ko) 2019-02-28 2022-03-08 주식회사 프로카젠 각 유전 변이 정보에 개별적인 가중치를 부여한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102371654B1 (ko) 2019-02-28 2022-03-08 주식회사 프로카젠 유전 변이의 개수에 따른 예측력을 고려한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체

Also Published As

Publication number Publication date
IL200197A (en) 2014-07-31
CN102317470A (zh) 2012-01-11
US8865400B2 (en) 2014-10-21
WO2008096375A3 (en) 2008-12-18
EP2115171B1 (en) 2015-01-21
IN2009DN05722A (enExample) 2015-07-24
SG193026A1 (en) 2013-09-30
BRPI0807236A2 (pt) 2019-09-24
MX2009008461A (es) 2009-08-17
CA2677994A1 (en) 2008-08-14
EP2522743A2 (en) 2012-11-14
NZ579401A (en) 2012-03-30
WO2008096375A2 (en) 2008-08-14
EP2522743A3 (en) 2013-08-07
US20100041037A1 (en) 2010-02-18
AU2008212117A1 (en) 2008-08-14
IL200197A0 (en) 2010-04-29
EP2115171A2 (en) 2009-11-11
AU2008212117B2 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
JP5631000B2 (ja) Ｃｈｒ８ｑ２４．２１上の癌感受性変異体
US8865400B2 (en) Genetic variants contributing to risk of prostate cancer
JP5676245B2 (ja) 乳癌のリスクアセスメント、診断、予後診断および治療における使用のためのマーカーとしてのｃｈｒ２およびｃｈｒ１６の遺伝的変異
CN102144036B (zh) 用于乳腺癌风险评估的遗传变型
NZ581858A (en) Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
JP2011530306A (ja) 甲状腺癌のリスクアセスメントに有用な遺伝的変異
WO2010128530A1 (en) Genetic variants contributing to risk of prostate cancer
JP2014097060A (ja) ２型糖尿病の遺伝的感受性変異体
AU2008331069B2 (en) Genetic variants on CHR HQ and 6Q as markers for prostate and colorectal cancer predisposition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130530

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140604

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140910

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150128

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20150522